Lunai Bioworks Inc.
Lunai Bioworks Inc. is an AI-powered company at the intersection of drug discovery, diagnostics, and biodefense. The company integrates generative AI, proprietary neurotoxicity and chemical datasets, multi-omics, and high-throughput in vivo models to identify and validate therapeutic targets, biomarkers, and to safeguard against dual-use biosecurity risks. Lunai Bioworks partners with academia, industry, and government to advance safe and responsible AI-enabled biomedical innovation, spanning oncology, neurology, precision medicine, and countermeasure development for chemical and biological threats.
Industries
N/A
Nr. of Employees
small (1-50)
Lunai Bioworks Inc.
3400 Cottage Way, Suite G2, #32562, Sacramento, California 95825, USA
Products
AI-driven drug discovery platform
Integrated system combining multi-omics data, machine learning, generative AI, and in vivo validation to enable target identification and prioritization, risk prediction, and safe compound generation.
AI-driven drug discovery platform
Integrated system combining multi-omics data, machine learning, generative AI, and in vivo validation to enable target identification and prioritization, risk prediction, and safe compound generation.
Expertise Areas
- Drug discovery using AI and phenomics
- Biomarker identification and validation
- Patient stratification for precision medicine
- Translational neurology and oncology research
Key Technologies
- Machine learning
- Generative AI
- Transformer-based risk intelligence
- High-throughput phenotypic screening
Key People
Chief Executive Officer
Chief Scientific Officer (BioSymetrics subsidiary)
Chief Executive Officer
Chief Scientific Officer (BioSymetrics subsidiary)
News & Updates
Received a multi-year Small Business Technology Transfer (STTR) grant from NIH to expand the AI-driven translational platform.
Notice of Allowance for computational data harmonization methods for drug discovery and diagnostics.
Study highlighted new prognostic protein biomarkers in Duchenne muscular dystrophy, enabling improved disease monitoring and clinical trial design.
Progress update on AI-driven preclinical biomarker discovery, emphasizing phenogrouping and multimodal analysis in Parkinson's disease.
Usage of AI models and in vivo assay data for rapid detection and mitigation of neurotoxic threats.
Announcement of an AI-based platform for patient stratification, biomarker discovery, and in silico compound screening in neurological diseases.
Received a multi-year Small Business Technology Transfer (STTR) grant from NIH to expand the AI-driven translational platform.
Notice of Allowance for computational data harmonization methods for drug discovery and diagnostics.
Study highlighted new prognostic protein biomarkers in Duchenne muscular dystrophy, enabling improved disease monitoring and clinical trial design.
Progress update on AI-driven preclinical biomarker discovery, emphasizing phenogrouping and multimodal analysis in Parkinson's disease.
Usage of AI models and in vivo assay data for rapid detection and mitigation of neurotoxic threats.
Announcement of an AI-based platform for patient stratification, biomarker discovery, and in silico compound screening in neurological diseases.